Loading
A phase 2 trial of Denileukin diftitox in Ovarian cancer, run by The University of Texas Health Science Center at San Antonio, completed.
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer is a phase 2 interventional study registered as NCT00880360 by The University of Texas Health Science Center at San Antonio, with 19 participants recorded, started 2007-02 and reaching its primary completion in 2010-04. Interventions recorded: Ontak. Conditions recorded: Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer, Fallopian Tube Carcinoma.
Linked to the drug Denileukin diftitox because the registry names it among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
19 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2012-10-19), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of Participants Demonstrating Clinical Responseprimary | Ontak | 19 | 19 participants | - | - | link |
Shares Denileukin diftitox and the tag pipeline.
Shares Denileukin diftitox and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.